HERCULES, Calif. and Houston, Texas— November 4, 2022 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in…
Publication Highlight –
QASeq: Simultaneous Ultrasensitive Detection of CNVs and Mutations from FFPE Tissue and cfDNA
Accelerating Precision Oncology Worldwide
Clinical and Research Laboratories
At NuProbe, we are developing innovative assays to accelerate cancer research. Our products allow laboratories to detect and quantify low-abundant variants across multiple platforms from both cell-free DNA and tissue specimens. Contact us today to learn more.
We provide assay development and testing services to support all stages of biomarker detection programs. Our flexible platform utilizes proprietary technologies to deliver best-in-class sensitivity from solid tumor and liquid biopsy. Contact one of our experts today to find out what NuProbe can do for you.
News & Press Releases
Houston, TX, Jun 02, 2022 — NuProbe Global, a genomics and molecular diagnostics company, announces the close of its $50M…
SADDLE approach uses computational primer design to minimize primer-dimer formation, and thus does not require enzymatic primers and primer-dimer removal.
MAR 30-31, 2023
NextGen Omics US
APR 14-19, 2023
AACR Annual Meeting
JUN 2-6, 2023
ASCO Annual Meeting